Reference | Animal models | Cell lines | Methods | Drugs | Effects |
---|---|---|---|---|---|
Nude mice | Pan-4JCK | ECT | Bleomycin | Tumour regression after 89 days | |
Carboplatin | |||||
Mitomicin C | |||||
Nude mice | BxPc3 | ECT | Cisplatin | Tumour regression after 28 days | |
Doxorubicin | |||||
Fluruoracil | |||||
Golden | PC-1 | ECT | Bleomycin | 100% complete response rate in subcutaneous tumours, 25% response rate in orthotopic tumours | |
Syrian | |||||
hamster |
Reference | Cell lines | Drugs | IC50 (P value) | Methods | EP parameters |
---|---|---|---|---|---|
PANC1 | Bleomycin | < 0.0001 | MTS assay | 8 pulses, 100 μs of duration, 5 Hz | |
MiaPaCa2 | Cisplatin | ≤ 0.0001 | FACS | ||
PANC1 | Gemcitabine | < 0.0001 | MTS assay | high intensity, low duration (microseconds) pulses; low intensity and long duration pulses (milliseconds). | |
PANC28 | ≤ 0.0001 |
Reference | No. of patients | Stage of pancreatic cancer | Results |
---|---|---|---|
Bagla | 78 | Stage III | No residual disease and a decreasing cancer antigen 19-9 level. |
Mansson | 5 | No serious treatment-related adverse events were observed. | |
Paiella | 10 | Stage III | Overall survival of 7.5 months |
Martin | 54 | Stage III | Improvement in local progression-free survival (14 |
Martin | 48 | Stage III | No significant vascular complications were seen, and of the high-grade complications, bleeding (2), biliary complications (3) and DVT/PE (3) were the most common. |